A two decade-long journey seeking US Food and Drug Administration approval of sunscreen UV filter BEMT is nearing its end, according to DSM-Firmenich’s Carl D’Ruiz. DSM-Firmenich’s experience speaks to the complexities and costs that sponsors face in the US in bringing new active ingredients to the OTC sunscreen products category.
DSM-Firmenich says UV filter bemotrizinol appears on track to reach the US after more than 20 years of working toward Food and Drug Administration approval and spending approximately $20m in the process.
That would make BEMT the first sunscreen active ingredient added to the agency’s OTC Sunscreen Drug Monograph in 25 years.